Skip to content
Clinical ResearchResearch compound

Kisspeptin‑10

Experimental peptide that stimulates testosterone production through a brain signal; only small human studies exist, banned in sport.

Kisspeptin-10 vial

DETAILED OVERVIEW

What is Kisspeptin-10?

Kisspeptin-10 is a peptide of ten amino acids, that is, a short protein chain, and the most active piece of kisspeptin, a signalling substance the body makes itself. It is an experimental compound and has not yet been approved as a medicine. In the brain it sets off the signal that leads, via the pituitary gland, to testosterone production in the testicle; steroid users therefore try it to restart their own hormone production.

In human studies, testosterone levels jumped within one to two hours of an injection, but so far only a few smaller studies have been done. The effect is a short burst; a lasting restart would need a repeating rhythmic signal, and with a continuous signal the receptors become insensitive. Side effects include headache, mood swings, reactions at the injection site and a rise in estrogen; non-sterile self-injection can cause infection, and long-term safety data are limited. It is contraindicated with hormone-sensitive tumors and in pregnancy. It is banned year-round in competitive sport.

Mechanism

Stimulates the brain's kisspeptin receptor; GnRH, then testosterone, rises

Half-life

~28 minutes (very short – pulsatility pattern is essential)

Onset

LH/FSH spike 1-2 hours after SC

Legal status

Not approved; phase II trial ongoing; banned in sport (WADA)

Data console

Lab data

Androgenic:AnabolicN/A (hypothalamic peptide, NOT AAS)
AR bindingGPR54 (KISS1R) Ki ~1-3 nM, high-affinity…
Active half-life~28 minutes (parent fragment active; metabolite fragments inactive)
Detection windowWADA-accredited LC-MS/MS sparse – peptide detection from urine sample 24-48 hours (research context, limited data).
AromatizationIndirect: hypothalamic GnRH stimulus → LH/FSH → testicular Test → peripheral E2 conversion. Magnitude moderate, similar to HCG-axis.
HepatotoxicityNo hepatic stress – peptide SC injection.

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Transient LH/FSH and testosterone surge: rapid hormonal swings that may cause headache, mood lability and short-term libido changes, as documented in clinical trials.
  • Receptor desensitization with continuous, non-pulsatile dosing: chronic steady GPR54/GnRH stimulation can paradoxically downregulate the axis and cause LH suppression (the known mechanism of GnRH-agonist therapy).
  • Injection-site reactions: subcutaneous administration can cause redness, pain, itching or swelling at the site; this accumulates with frequent daily/hourly dosing.
  • Sterility and infection risk: self-handling of research-grade lyophilized peptide (reconstitution, frequent SC injection) can cause skin and soft-tissue infection with non-sterile technique.
  • Secondary estradiol rise: peripheral aromatization of the induced testosterone can raise E2, potentially causing water retention or tenderness, of similar magnitude to the HCG axis.
  • Fertility/reproductive neuroendocrine effects: kisspeptin strongly drives the reproductive axis, so uncontrolled dosing can disrupt natural cyclicity and spermatogenesis; long-term human safety data are limited.
  • Peptide quality risk: UGL sources without HPLC/mass-spec certification may contain degraded or pseudo-peptide, leading to ineffectiveness or unpredictable reactions.

Contraindications · 7

  • Pregnancy and breastfeeding, plus pregnant-partner contact risk: kisspeptin is central to reproductive neuroendocrine regulation; avoid due to theoretical fetal HPG-axis effects.
  • Hormone-sensitive (androgen- or estrogen-dependent) cancer, e.g. prostate or breast cancer: the induced LH/FSH and testosterone rise can worsen the disease.
  • Concurrent GnRH-agonist therapy (Lupron, Zoladex) or other GnRH-pathway agents (gonadorelin): not recommended due to overlapping mechanism and theoretical receptor interaction.
  • Structural hypothalamic-pituitary damage or pituitary insufficiency: a peptide acting at the top of the axis cannot substitute downstream replacement where the pituitary response is absent.
  • Known hypersensitivity to kisspeptin or formulation excipients (e.g. bacteriostatic water, benzyl alcohol).
  • Competitive athletes: prohibited both in- and out-of-competition under WADA S2 Peptide Hormones.
  • Untrained self-administering user: the pulsatile pump protocol and sterile reconstitution/injection technique require specialized knowledge; contraindicated without it.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Kisspeptin‑10?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.